Stock ECX EPIGENOMICS AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Epigenomics AG Deutsche Boerse AG

Equities

ECX

DE000A11QW50

End-of-day quote Deutsche Boerse AG
Other stock markets
 06:00:00 2024-02-04 pm EST 		5-day change 1st Jan Change
1.785 EUR -1.92% Intraday chart for Epigenomics AG +9.51% -4.03%
Mar. 14 Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
EPIGENOMICS AG Stock Epigenomics AG
-4.03% 1.51M -
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.45% 10.82B
A-
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+43.17% 3.25B
D+
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-35.86% 2.11B
C
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-17.21% 2.08B -
B-
VERACYTE, INC. Stock Veracyte, Inc.
-29.81% 1.48B
C+
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+17.56% 1.02B
B-
SEEGENE, INC. Stock Seegene, Inc.
-4.37% 733M
C+
CAREDX, INC Stock CareDx, Inc
-37.00% 391M
C-
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-46.94% 377M
C-
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. ECX Stock
  4. ECX Stock
  5. Ratings Epigenomics AG